Ovarian Cancer | Clinical

Historical and Current Data Inform the Ovarian Treatment Landscape for Practicing Oncologists

February 21, 2021

Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.

Rucaparib Improves PFS in Patent With BRCA Mutation-Positive Relapsed Ovarian Cancer

December 21, 2020

Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.

Olaparib Shows PFS Benefit at 5-Year Follow-Up in BRCA Ovarian Cancer

September 18, 2020

Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.